Key result
Post-MI β-blocker doses ≥50% of target show similar re-infarction or death risk to <50% doses.
Why the study?
Dose-dependent effects of β-blockers on survival and cardiovascular outcomes after myocardial infarction are not well understood.
Does ≥50% of the target β-blocker dose reduce re-infarction or all-cause death in patients with first-time myocardial infarction compared to <50% of the target dose?
Observational (n=97,575)
Yes
Does ≥50% of the target β-blocker dose reduce re-infarction or all-cause death in patients with first-time myocardial infarction compared to <50% of the target dose?
Discharge with ≥50% of the target β-blocker dose after first-time myocardial infarction was not associated with improved cardiovascular outcomes up to 5 years compared to lower doses.
Answers are grounded in this paper and cite their sources.
Higher β-blocker doses showed no outcome benefit after MI; leaves open optimal dosing pending randomized trials.
AIMS: Dose-dependent effects of β-blockers on survival and cardiovascular outcomes after myocardial infarction (MI) are not well understood. We investigated the long-term risk of cardiovascular events in patients with different doses of β-blockers after MI. METHODS AND RESULTS: This was a nationwide observational study linking morbidity, mortality, socioeconomic, and medication data from Swedish national registries. Between 2006 and 2015, 97 575 unique patients with first-time MI were included. In total, 33 126 (33.9%) patients were discharged with ≥50% of the target β-blocker dose and 64 449 (66.1%) patients with <50% of the target β-blocker dose used in previous randomized trials. The primary composite endpoint was re-infarction or all-cause death within 1 year from discharge. Multivariable adjusted 1-year follow-up estimates using mixed effects Cox regression [HR (95% CI)] showed that patients treated with ≥50% of the target dose had a similar risk of the composite endpoint [1.03 (0.99-1.08)] and a somewhat higher risk when stroke, atrial fibrillation, or heart failure hospitalization were added to the composite endpoint [1.08 (1.04-1.12)], compared with patients on <50% of the target β-blocker dose. Results remained similar up to 5 years of follow-up and consistent across relevant patient subgroups, including patients who developed heart failure during the index hospitalization. CONCLUSIONS: In contrast to doses of β-blockers used in previous trials, ≥50% of the target β-blocker dose was not associated with superior cardiovascular outcomes up to 5 years as compared with <50% of the target dose. Contemporary randomized clinical trials are needed to clarify the optimal dose of β-blockers after MI.
No takes yet. Share an insight, caveat, or question.
Mars et al. (2020) conducted an observational in first-time myocardial infarction (n=97,575). β-blockers vs. <50% of the target dose was evaluated on re-infarction or all-cause death within 1 year from discharge (HR 1.03, 95% CI 0.99-1.08). Treatment with ≥50% of the target β-blocker dose after MI had a similar risk of re-infarction or death at 1 year compared with <50% of the target dose.
Synapse has enriched 10 related papers. Consider them for comparative context: